Compounded vs. FDA-Approved Weight-Loss Medicines

Two websites may advertise semaglutide at very different prices. One names an FDA-approved product. The other describes a compounded version, perhaps using phrases such as “personalized” or “same active ingredient.”

Those descriptions can sound interchangeable. They are not equivalent regulatory categories, and the distinction matters when you are deciding what would be prescribed and dispensed.

Compounding has legitimate medical uses. Understanding those uses also means understanding what FDA approval does—and does not—tell you about a particular product.

Start with the finished medicine

FDA approval applies to a specific drug product and its approved uses. A compounded preparation does not become an FDA-approved product simply because an approved medicine contains the same named ingredient.

The FDA does not review compounded drugs for safety, effectiveness, and quality before they are marketed. That does not mean every compounded medicine is harmful. It means the assurance provided by the drug approval process is absent. FDA compounding questions and answers.

An FDA-approved generic is different again: it has gone through the applicable FDA approval pathway. Calling a compounded product a “generic” can obscure this distinction.

Why compounding exists

A person may need a formulation an approved product cannot provide—for example, one without an ingredient they are allergic to. In appropriate circumstances, compounding can meet an individual medical need.

But the reason needs to be specific. The FDA recommends using compounded drugs when a patient’s medical needs cannot be met by an approved drug. There are also rules affecting compounding during drug shortages; an old shortage-related advertisement does not establish that a product can lawfully be compounded today.

Ask the prescriber what need the proposed preparation addresses, whether an approved option can meet it, and what evidence supports the choice. The answer should describe your care, rather than relying only on the word “custom.”

The label needs to explain what you are getting

For compounded GLP-1 products, the FDA has reported concerns involving dosing mistakes, products with misleading pharmacy information, and forms of semaglutide that differ from the ingredient used in approved products. In particular, semaglutide sodium and semaglutide acetate are different active ingredients from the base form used in approved medicines. FDA concerns about unapproved GLP-1 drugs.

If a prescription comes in a vial, understand that milligrams, milliliters, and syringe “units” are different measurements. A volume instruction cannot be carried from one concentration to another as if the amount of medicine stayed the same.

Have the dispensing pharmacist explain the exact preparation and demonstrate how its instructions match the supplied device. Do not borrow a dosing chart from a social-media group or reuse instructions from a different product.

Check who actually prepared and dispensed it

The name on the marketing website may differ from the pharmacy name. Ask for the dispensing pharmacy and, when relevant, the compounder. Verify the pharmacy through the state board rather than relying solely on a logo or seal.

The FDA’s online-pharmacy guidance also recommends checking for a valid prescription requirement and a pharmacist who can answer questions.

When medication arrives, unresolved problems with the label, instructions, packaging, or storage conditions should be addressed before use. The FDA specifically advises against using injectable GLP-1 drugs that arrive warm or without adequate refrigeration. Contact the pharmacy and prescribing team rather than guessing that a questionable shipment is fine.

Retatrutide is a separate issue

As of October 19, 2026, the FDA states that retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law. An online seller calling it “compounded” or “research use only” does not turn it into an approved treatment.

Clinical research and retail availability are different things. Our retatrutide explainer discusses the compound’s research status and why that distinction matters.

Make the comparison before making the purchase

Price can be a real barrier, and wanting an affordable option is reasonable. A useful conversation still needs the full medicine name, approval status, pharmacy identity, clinical reason for the prescription, and a way to get help.

If you are already receiving a compounded medicine, bring those details to your prescriber or pharmacist. This article cannot determine the quality or appropriateness of your individual preparation.

The immediate goal is a clear account of what you are taking and why. You should not have to infer that from advertising language.